ASH News Daily 2016 - Issue 2 - A-1


ASH NewS DAily
®

58th Annual Meeting of the American Society of Hematology
Issue 2, Section A
Sunday, December 4, 2016
San Diego, CA
Read this issue online at

www.hematology.org/ashnewsdaily2016_sunday
Follow us on Twitter using #ASH16

Schedule
7:00 - 9:00 a.m.
Hematology Course Directors' Workshop
Hilton San Diego Bayfront
(Aqua Salon ABC)
11:15 a.m. - 12:15 p.m.
Continuing Conversations
with the Speakers
Manchester Grand Hyatt San Diego
(La Jolla AB; Old Town AB)
11:15 a.m. - 12:15 p.m.
Featured Topic Discussion:
Gene Editing - Not Just CRISPR
San Diego Convention Center
(Room 5AB)
11:15 a.m. - 12:30 p.m.
Social Media and Clinical Trials:
Physicians, Pharma, and Patients
San Diego Convention Center
(Room 28ABCD)
11:15 a.m. - 12:30 p.m.
ASH Practice Partnership Lunch
Marriott Marquis San Diego Marina
(Marina Ballroom G)

The Times They Are a-Changin'
By R. Frank Cornell, MD

M

usician Bob Dylan was
awarded the Nobel Prize
in literature this year for
"having created new poetic expressions within the great American song tradition," according to
the Swedish Nobel Committee.
His song released in 1964, "The
Times They Are a-Changin'" was
an attempt to promote an anthem
of change during a time at which
both the civil rights and folk music
movements were allied together.
The times are indeed changing in
hematology with a plethora of newly approved agents by the U.S. Food
and Drug Administration (FDA).
2015 was the year of myeloma with
the advent of panobinostat, elotuzumab, ixazomib, daratumumab,
and carfilzomib in combination
with lenalidomide and dexametha-

sone. This year also saw new therapeutic options for Hodgkin disease,
and hemostatic agents for von Willebrand disease and hemophilia.
The 2016 session started with
Dr. Stephen Ansell discussing the
recent approval of nivolumab and
post-transplantation brentuximab
vedotin for the treatment of Hodgkin lymphoma (HL). Dr. Ansell reviewed that nivolumab is a fully
human programmed death-1 (PD-1)
monoclonal antibody targeting the
immune checkpoint pathway. During this session Dr. Ansell reviewed
how PD-1 blockade is highly relevant for treatment of HD; however, there are many unanswered
mechanistic questions that are being researched actively. In the initial phase I trial of 23 patients, the
response rate was 87 percent with
17 percent complete responses.
More importantly, the responses

12:30 - 1:30 p.m.
ASH/EHA Joint Symposium
San Diego Convention Center
(Hall AB)

Return of the MAC

1:30 - 2:00 p.m.
Announcement of Wallace H. Coulter Award
San Diego Convention Center
(Hall AB)

A

2:00 - 4:00 p.m.
Plenary Scientific Session
4:30 - 6:00 p.m.
Blood and Beyond: Blood: An Epic
History of Medicine and Commerce
San Diego Convention Center
(Ballroom 20A)

By Rakhi Naik, MD, MHS
lthough the membrane attack complex (MAC) was
most certainly the furthest
thing from Winston Churchill's
mind when he coined the idiom "a
riddle wrapped up in a mystery in-

side an enigma" during World War
II, there is no phrase more accurate
to describe how many hematologists feel about the complement system. Blank stares, confused faces,
and furrowed brows are commonplace to Dr. Charles Parker, who
chaired yesterday's education ses-

IN THIS SECTION
Myeloma
A-8
Blood History
A-9
Social Media
A-10
AML
A-12
Maternal Mortality
A-25

Audience members listen to Dr. Charles Parker at Saturday afternoon's
update on diagnosis and treatment of paroxysmal nocturnal hemoglobinuria
at the "Complement Disorders and Hematologic Consequences" session.

Dr. Stephen Ansell delivers his presentation on Saturday.

were durable, with an 83 percent
survival rate at two years out from
treatment. Other agents, such as
pembrolizumab, have also demonstrated similar results with HL and
are being studied. Per Dr. Ansell,
"the exciting part moving forward
is to bring this treatment into standard practice and research novel
»» FDA Page A-3

sion titled "Complement Disorders
and Hematologic Consequences,"
and who has dedicated his career
to studying the quintessential complement-mediated disease - paroxysmal nocturnal hemoglobinurea
(PNH). "To most, the complement
system resides in one of the dark
corners of hematology, only dimly
illuminated when the direct antibody test is reported as positive for
C3," he mused.
However, deciphering the complement system is no longer the responsibility of PNH experts alone.
Atypical hemolytic uremic syndrome (aHUS) and cold agglutinin
disease now join the group of complement disorders, and many other
diseases may soon follow. Much to
the chagrin of befuddled hematologists who have relegated their medical school teachings of the complement system to the depths of their
brains, we have now arrived at the
"return of the MAC."
But there is no reason for panic. As the speakers at yesterday's
»» MAC Page A-24


http://www.hematology.org/ashnewsdaily2016_sunday

Table of Contents for the Digital Edition of ASH News Daily 2016 - Issue 2

ASH News Daily 2016 - Issue 2 - A-1
ASH News Daily 2016 - Issue 2 - A-2
ASH News Daily 2016 - Issue 2 - A-3
ASH News Daily 2016 - Issue 2 - A-4
ASH News Daily 2016 - Issue 2 - A-5
ASH News Daily 2016 - Issue 2 - A-6
ASH News Daily 2016 - Issue 2 - A-7
ASH News Daily 2016 - Issue 2 - A-8
ASH News Daily 2016 - Issue 2 - A-9
ASH News Daily 2016 - Issue 2 - A-10
ASH News Daily 2016 - Issue 2 - A-11
ASH News Daily 2016 - Issue 2 - A-12
ASH News Daily 2016 - Issue 2 - A-13
ASH News Daily 2016 - Issue 2 - A-14
ASH News Daily 2016 - Issue 2 - A-15
ASH News Daily 2016 - Issue 2 - A-16
ASH News Daily 2016 - Issue 2 - A-17
ASH News Daily 2016 - Issue 2 - A-18
ASH News Daily 2016 - Issue 2 - A-19
ASH News Daily 2016 - Issue 2 - A-20
ASH News Daily 2016 - Issue 2 - A-21
ASH News Daily 2016 - Issue 2 - A-22
ASH News Daily 2016 - Issue 2 - A-23
ASH News Daily 2016 - Issue 2 - A-24
ASH News Daily 2016 - Issue 2 - A-25
ASH News Daily 2016 - Issue 2 - A-26
ASH News Daily 2016 - Issue 2 - B-1
ASH News Daily 2016 - Issue 2 - B-2
ASH News Daily 2016 - Issue 2 - B-3
ASH News Daily 2016 - Issue 2 - B-4
ASH News Daily 2016 - Issue 2 - B-5
ASH News Daily 2016 - Issue 2 - B-6
ASH News Daily 2016 - Issue 2 - B-7
ASH News Daily 2016 - Issue 2 - B-8
ASH News Daily 2016 - Issue 2 - B-9
ASH News Daily 2016 - Issue 2 - B-10
ASH News Daily 2016 - Issue 2 - B-11
ASH News Daily 2016 - Issue 2 - B-12
ASH News Daily 2016 - Issue 2 - B-13
ASH News Daily 2016 - Issue 2 - B-14
ASH News Daily 2016 - Issue 2 - B-15
ASH News Daily 2016 - Issue 2 - B-16
ASH News Daily 2016 - Issue 2 - B-17
ASH News Daily 2016 - Issue 2 - B-18
ASH News Daily 2016 - Issue 2 - B-19
ASH News Daily 2016 - Issue 2 - B-20
ASH News Daily 2016 - Issue 2 - B-21
ASH News Daily 2016 - Issue 2 - B-22
ASH News Daily 2016 - Issue 2 - B-23
ASH News Daily 2016 - Issue 2 - B-24
ASH News Daily 2016 - Issue 2 - B-25
ASH News Daily 2016 - Issue 2 - B-26
ASH News Daily 2016 - Issue 2 - B-27
ASH News Daily 2016 - Issue 2 - B-28
ASH News Daily 2016 - Issue 2 - B-29
ASH News Daily 2016 - Issue 2 - B-30
ASH News Daily 2016 - Issue 2 - B-31
ASH News Daily 2016 - Issue 2 - B-32
ASH News Daily 2016 - Issue 2 - B-33
ASH News Daily 2016 - Issue 2 - B-34
ASH News Daily 2016 - Issue 2 - B-35
ASH News Daily 2016 - Issue 2 - B-36
ASH News Daily 2016 - Issue 2 - B-37
ASH News Daily 2016 - Issue 2 - B-38
ASH News Daily 2016 - Issue 2 - B-39
ASH News Daily 2016 - Issue 2 - B-40
ASH News Daily 2016 - Issue 2 - B-41
ASH News Daily 2016 - Issue 2 - B-42
ASH News Daily 2016 - Issue 2 - B-43
ASH News Daily 2016 - Issue 2 - B-44
ASH News Daily 2016 - Issue 2 - B-45
ASH News Daily 2016 - Issue 2 - B-46
ASH News Daily 2016 - Issue 2 - B-47
ASH News Daily 2016 - Issue 2 - B-48
ASH News Daily 2016 - Issue 2 - C-1
ASH News Daily 2016 - Issue 2 - C-2
ASH News Daily 2016 - Issue 2 - C-3
ASH News Daily 2016 - Issue 2 - C-4
ASH News Daily 2016 - Issue 2 - C-5
ASH News Daily 2016 - Issue 2 - C-6
ASH News Daily 2016 - Issue 2 - C-7
ASH News Daily 2016 - Issue 2 - C-8
ASH News Daily 2016 - Issue 2 - C-9
ASH News Daily 2016 - Issue 2 - C-10
ASH News Daily 2016 - Issue 2 - C-11
ASH News Daily 2016 - Issue 2 - C-12
ASH News Daily 2016 - Issue 2 - C-13
ASH News Daily 2016 - Issue 2 - C-14
ASH News Daily 2016 - Issue 2 - C-15
ASH News Daily 2016 - Issue 2 - C-16
ASH News Daily 2016 - Issue 2 - C-17
ASH News Daily 2016 - Issue 2 - C-18
ASH News Daily 2016 - Issue 2 - C-19
ASH News Daily 2016 - Issue 2 - C-20
ASH News Daily 2016 - Issue 2 - C-21
ASH News Daily 2016 - Issue 2 - C-22
ASH News Daily 2016 - Issue 2 - C-23
ASH News Daily 2016 - Issue 2 - C-24
ASH News Daily 2016 - Issue 2 - C-25
ASH News Daily 2016 - Issue 2 - C-26
http://www.nxtbookMEDIA.com